Welcome to our dedicated page for Pharming Group N.V. SEC filings (Ticker: PHAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial protocols, biologics manufacturing details, and royalty milestones make Pharming Group N.V.’s SEC disclosures hard to navigate—even seasoned biotech analysts admit it takes hours to isolate the data behind Ruconest sales or Joenja’s APDS launch. If you have ever Googled “Pharming Group N.V. SEC filings explained simply” or wondered where insider stock sale notices hide, you know the challenge.
Stock Titan’s AI tackles that complexity head-on. We deliver real-time alerts the moment a Form 4 drops, so “Pharming Group N.V. insider trading Form 4 transactions” appear on your dashboard within seconds. Our natural-language engine distills each 20-F (the foreign-issuer equivalent of an annual report 10-K) into concise bullet points—clinical-trial timelines, U.S. revenue split, R&D tax credits—turning a 300-page tome into a five-minute read. Interim results arrive as 6-K reports, tagged under “Pharming Group N.V. quarterly earnings report 10-Q filing” so you never miss updated HAE prescription data or APDS patient-enrolment numbers. Need to decode a sudden capital raise? Our analysis links each F-3 registration to cash-runway projections.
Use the platform to:
- Track “Pharming Group N.V. executive stock transactions Form 4” in real time
- Scan “Pharming Group N.V. proxy statement executive compensation” without digging through appendices
- Read “Pharming Group N.V. earnings report filing analysis” that compares quarter-over-quarter Ruconest sales
- Get “Pharming Group N.V. 8-K material events explained” when trial data or licensing deals break
- Access an archive of “Pharming Group N.V. annual report 10-K simplified” style summaries powered by AI
Whether you are modelling future leniolisib royalties or monitoring FDA-related 8-K updates, Stock Titan turns “understanding Pharming Group N.V. SEC documents with AI” from a wish into today’s workflow.
Pharming Group N.V. furnished a press release noting that 12 abstracts were accepted for presentation at the 2025 ACAAI Annual Scientific Meeting in Orlando on November 6–10. The program includes five posters with new clinical, economic, and comparative data on RUCONEST for on-demand treatment of hereditary angioedema, and seven posters with real‑world effectiveness and pediatric data on Joenja (leniolisib) in APDS, plus caregiver and burden-of-illness insights.
Topics span indirect treatment comparisons, cost‑effectiveness, time‑to‑event endpoint analyses, patient‑reported outcomes, adherence, healthcare utilization, and registry characterization. ePosters will be accessible to registered attendees beginning November 6 at 08:00 EST via ACAAI’s website.
Pharming Group announced the FDA has accepted its supplemental NDA seeking approval of leniolisib (Joenja) for children aged 4–11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The application received Priority Review with a PDUFA target action date of January 31, 2026. The sNDA is supported by positive data from a multinational, single-arm Phase III study in 4–11-year-olds showing, over 12 weeks, reductions in lymphadenopathy and increases in naïve B cells, indicating correction of the underlying immune defect; the submission also included safety data from 8 months of treatment. There are no approved treatments globally for children under 12 with APDS. Leniolisib is already approved in the U.S. for patients aged 12 and older (March 2023).
Pharming Group announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The release states Mr. Lynard has over 20 years of global finance leadership in life sciences, including recent CFO roles at Schoeller Allibert and Zentiva and senior finance roles at Gilead Sciences where he served as Senior Vice President and CFO for Global Commercial Operations, R&D and Manufacturing.
The company frames the hire as strengthening financial leadership following strong first half 2025 financial results and supporting Pharming's growth strategy and commercial and pipeline catalysts. Mr. Lynard holds an MSc in Business Economics and Auditing and an executive MBA from IMD.
FAQ
What is the current stock price of Pharming Group N.V. (PHAR)?
What is the market cap of Pharming Group N.V. (PHAR)?
